To this end, LGM possesses a DNA database of patients with different pathologies which it has put to work to identify new therapeutic targets in order to test newly synthesized compounds. Currently LGM has an arsenal of more than 600 products available for testing against the aforementioned targets.
LGM is a value proposition for developing first-in-class medicines from an ever-expanding proprietary chemo-library of thousands of products designed to be tested on currently identified targets.
LGM’s development strategy ranges from early-stage chemical synthesis and hit finding to clinical proof of concept.
Through this process, LGM has obtained compounds with high added value in the treatment of a variety of diseases and pathological processes such as obesity, fibrosis, heart failure, Alzheimer’s disease and cancer.